Skip to content
ChickenStockChickenStock
Research298380
ABL Bio logo

ABL Bio (298380) stock

KOSDAQ · Biotechnology

KRW 38,600-5.04%(-2,050)

As of Nov 16, 11:21 AM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-27.23x

Net loss — not comparable

P/B

12.57x

P/S

62.87x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 11, 2026KRW 19.7 billion-KRW 16.8 billion-KRW 15 billion-74.0%
Q1 2026Consolidated · Filed May 8, 2026KRW 13.1 billion-KRW 17.2 billion-KRW 14.7 billion+506.8%
Q4 2025Consolidated · Filed Mar 12, 2026KRW 0-KRW 29.7 billion-KRW 28.2 billion—
Q3 2025Consolidated · Filed Nov 11, 2025KRW 1.4 billion-KRW 22.4 billion-KRW 21.3 billion-81.8%
Q2 2025Consolidated · Filed Aug 12, 2025KRW 75.7 billionKRW 40.7 billionKRW 39.8 billion+797.2%
Q1 2025Consolidated · Filed May 13, 2025KRW 2.2 billion-KRW 29 billion-KRW 28.1 billion-72.7%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 12, 2026KRW 79.3 billion-KRW 40.4 billion-KRW 37.9 billion+137.6%
FY2024Consolidated · Filed Mar 13, 2025KRW 33.4 billion-KRW 59.4 billion-KRW 55.5 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
7.08%
Of trading value on Nov 13, 2026
Short-sale value
KRW 1.23 billion
Previous 20-day average 11.57%
Net short position
196,144 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
3,151,294 shares
As of Nov 13, 2026 · 5.63% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20267.08%KRW 1.23 billion
Nov 12, 202612.49%KRW 2.83 billion
Nov 11, 20263.33%KRW 1.29 billion
Nov 10, 20262.00%KRW 230 million
Nov 9, 20264.69%KRW 800 million
Nov 6, 20260.91%KRW 230 million
Nov 5, 20268.78%KRW 3.2 billion
Nov 4, 202611.19%KRW 2.18 billion
Nov 3, 202624.49%KRW 2.58 billion
Nov 2, 202614.58%KRW 1.76 billion

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

ABL Bio (298380) stock information

KOSDAQ

ABL Bio (298380) is listed on KOSDAQ. Its market capitalization is about KRW 2.2 trillion. On trailing-twelve-month earnings the P/E ratio is -27.23, and the P/B ratio is 12.57. Return on equity is -46.2%. These figures are computed in-house from official filings and are reference information only.

ABL Bio — frequently asked questions

What is the P/E ratio of ABL Bio (298380)?
On a trailing-twelve-month basis, 298380 trades at a P/E ratio of -27.23. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of ABL Bio?
298380 has a market capitalization of about KRW 2.2 trillion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.